Tumor inhibition in xenograft model of diffuse intrinsic pontine glioma via ultra-low and low-frequency magnetic field therapy

A low-frequency (DC-22.05 kHz), time-varying magnetic field signal (rfe_A1A) was tested against the human-derived SF8628 cell line, a diffuse intrinsic pontine glioma (DIPG). This study was done to determine the efficacy and mechanism of action of the rfe_A1A signal, in vitro and in vivo. In vitro, an acellular tubulin polymerization assay and an SF8628 cell culture assay increased tubulin polymerization rates and reduced cell division, respectively. Mouse survival models of DIPG, subsequently exposed to the rfe_A1A signal, demonstrated significantly longer survival times and biomarker changes in Ki67 expression, consistent with a slowdown in cell-division rates. The rfe_A1A signal significantly increased survival time in a DIPG model, a novel strategy tested in clinical studies and compassionate use cases. We tested a magnetic field signal (rfe_A1A) for its ability to slow down tumor growth. These tests included non-cell-based tests for how the signal works (protein assays), cell-based tests in a cancer cell line called SF8628 (slowing down the rate of how fast cells divide) and in mouse models of this disease (testing the rfe_A1A signal to see if mice – implanted with tumors- survive longer than the non-treated mice). Mice treated with the rfe_A1A signal survived longer than the non-treated mice. This new method of slowing down tumors has no observable side effects, does not damage other organs, and has the potential of prolonging survival and quality of life in children with DIPG and in adults with a brain cancer called glioblastoma.